ASAmy G. Starr

Amy G. Starr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy G. Starr has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Bhaskar Kallakury

    MedStar Georgetown University Hospital, Washington, DC, USA

    2 shared publications
  • Bhaskar V. Kallakury

    MedStar Georgetown University Hospital, Department of Pathology, 3800 Reservoir Rd NW, Medical Dental Building, SE 200, Washington, DC 20007, USA

    2 shared publications
  • Chaitra S. Ujjani

    Lombardi Comprehensive Cancer Center, Department of Hematology and Oncology, MedStar Georgetown University Hospital, 3800 Reservoir Rd. NW, Washington, DC 20007, USA

    2 shared publications
  • Dong Hyang Kwon

    Georgetown University Hospital, Washington, DC, USA

    2 shared publications
  • Joeffrey J. Chahine

    MedStar Georgetown University Hospital, Department of Pathology, 3800 Reservoir Rd NW, Medical Dental Building, SE 200, Washington, DC 20007, USA

    2 shared publications
  • Aa

    1 shared publication

Latest Publications

  • Open Access

    Cutaneous mucormycosis of the lower extremity leading amputation in two diabetic patients

    by Kathleen M. Coerdt, Elizabeth G. Zolper, Amy G. Starr, Kenneth L. Fan, Christopher E. Attinger, Karen K. Evans

    Mucormycosis is an invasive, rapidly progressive, life-threatening fungal infection, with a propensity for diabetic, immunosuppressed, and trauma patients. The classic rhinocerebral variation is most common in diabetic patients. While the cutaneous form is usually caused by direct inoculation in immunocompetent patients. Cutaneous mucormycosis manifests in soft tissue and risks involvement of underlying structures. Tibial osteomyelitis can also occur secondary to cutaneous mucormycosis but is rare. Limb salvage is typically successful after lower extremity cutaneous mucormycosis even when the bone is involved. Herein, we report two cases of lower extremity cutaneous mucormycosis in diabetic patients that presented as acute worsening of chronic pretibial ulcers. Despite aggressive antifungal therapy and surgical debridement, both ultimately required amputation. Such aggressive presentation has not been reported in the absence of major penetrating trauma, recent surgery, or burns.


  • Open Access

    Concurrent Diagnosis of Chronic Myeloid Leukemia and Follicular Lymphoma: An Unreported Presentation

    by Amy G. Starr, Sushma R. Jonna, Joeffrey J. Chahine, Bhaskar V. Kallakury, Chaitra S. Ujjani

    Lymphadenopathy in chronic myeloid leukemia (CML) is usually due to extramedullary involvement with accelerated or blast phases of the disease. The occurrence of non-Hodgkin lymphoma (NHL) as a synchronous malignancy with CML is rare. We report a case of a 73-year-old male who presented with dyspnea and right-sided lower extremity edema in the setting of leukocytosis. Bone marrow evaluation indicated a chronic phase chronic myeloid leukemia (CML), confirmed by molecular testing. Imaging of the chest for persistent dyspnea revealed supraclavicular and mediastinal lymphadenopathy. Biopsy of the cervical node showed expanded lymphoid follicles with atypical germinal centers that were positive for CD10, BCL-2, and BCL-6, consistent with follicular lymphoma (FL). Nodal PCR demonstrated clonal IGH and IGK gene rearrangements, and FISH analysis was positive for IGH-BCL-2 fusion. Together, these tests supported the diagnosis of FL. Additionally, the lymph node showed paracortical expansion by maturing pan-hematopoietic elements, no blastic groups, and positive RT-PCR analysis for BCR-ABL1, indicating concomitant involvement by chronic phase-CML. To our knowledge, this is the first reported case of a patient with a concurrent diagnosis of CML and FL.


  • Epstein-Barr Virus–Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge

    by Amy Starr, Dong Hyang Kwon, Bhaskar Kallakury

    Diffuse large B-cell lymphoma (DLBCL) is characterized by medium- to large-sized neoplastic cells that express a wide range of B-cell markers including CD19, CD20, CD22, and CD79a. Also, as this is a hematopoietic malignancy, there is expression of the leukocyte common antigen CD45. Lack of CD20 expression occurs in a specific rare heterogeneous subgroup of DLBCL including primary effusion lymphoma, plasmablastic lymphoma, ALK-positive large B-cell lymphoma, and large B-cell lymphoma arising in HHV8+ multicentric Castleman disease. In this article, we report a rare case of CD20- and CD45-negative Epstein-Barr virus–positive DLBCL in which the entities listed above were ruled out, thereby posing a significant diagnostic challenge. Arriving at the correct diagnosis of Epstein-Barr virus–positive DLBCL was supported by immunoreactivity for the B-cell transcription factor Oct-2 and the pan-B cell marker CD79a.


  • Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17)

    by Adam L. Booth, MD1; Diana Rodgers, MD2; Phillip Osehobo, MD, PhD2; Lalarukh K. Aftab, MD3; Mahmoud A. Eltorky, MD2; Heather L. Stevenson, MD, PhD11Department of Pathology, University of Texas Medical Branch, Galveston2Department of Pathology, WellStar Spa, Adam L. Booth, Diana Rodgers, Phillip Osehobo, Lalarukh K. Aftab, Mahmoud A. Eltorky, Heather L. Stevenson, Kai Wang, MD, PhD; Rongjun Guo, MD, PhDDepartment of Pathology, University of Alabama at Birmingham., Kai Wang, Rongjun Guo, et al.

    Article Citation: (2017) Abstracts and Case Studies From the College of American Pathologists 2017 Annual Meeting (CAP17). Archives of Pathology & Laboratory Medicine: September 2017, Vol. 141, No. 9, pp. e2-e191. https://doi.org/10.5858/arpa.2017-0238-AB